Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  OSE Immunotherapeutics    OSE   FR0012127173

OSE IMMUNOTHERAPEUTICS

(OSE)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Paris
02/11/2019 02/12/2019 02/13/2019 02/14/2019 02/15/2019 Date
4(c) 3.87(c) 3.82(c) 3.98(c) 4.12(c) Last
142 627 18 562 6 381 31 329 89 113 Volume
+12.04% -3.25% -1.29% +4.19% +3.52% Change
More quotes
Financials (EUR)
Sales 2018 18,8 M
EBIT 2018 1,60 M
Net income 2018 1,24 M
Finance 2018 7,60 M
Yield 2018 -
Sales 2019 20,8 M
EBIT 2019 -1,20 M
Net income 2019 -9,42 M
Finance 2019 15,1 M
Yield 2019 -
P/E ratio 2018 24,72
P/E ratio 2019
EV / Sales2018 2,84x
EV / Sales2019 2,22x
Capitalization 61,0 M
More Financials
Company
Following the merger with Effimune, OSE Pharma changed its corporate name to OSE Immunotherapeutics. The new group specializes in the development of innovative treatments to activate or regulate the immune system and restore system disorders in the fields of immuno-oncology, autoimmune diseases and... 
More about the company
Surperformance© ratings of OSE Immunotherapeutics
Trading Rating : Investor Rating :
More Ratings
Latest news on OSE IMMUNOTHERAPEUTICS
02/07OSE Immunotherapeutics  and Servier Announce First Option Within Global Licen..
GL
01/15OSE Immunotherapeutics Receives First Notice of Allowance of a Patent for Use..
GL
01/03OSE IMMUNOTHERAPEUTICS : to present at Biotech Showcase™ 2019 Conference D..
PU
01/03OSE IMMUNOTHERAPEUTICS : to present at Biotech Showcase™ 2019 Conference
AQ
2018OSE IMMUNOTHERAPEUTICS : Appoints Julien Perrier Chief Commercial Officer
AQ
2018OSE Immunotherapeutics Appoints Julien Perrier Chief Commercial Officer
GL
2018OSE IMMUNOTHERAPEUTICS : Invited to Present Mechanistic Data on Clinical Stage A..
AQ
2018OSE IMMUNOTHERAPEUTICS : Granted Belgian Authorization for Phase 1 Clinical Tria..
AQ
2018OSE IMMUNOTHERAPEUTICS : and Oncology Physician Network GERCOR Announce Initiati..
AQ
2018OSE IMMUNOTHERAPEUTICS : and Oncology Physician Network GERCOR Announce Initiati..
AQ
More news
Sector news : Biotechnology & Medical Research - NEC
02/15Bayer gains full Vitrakvi rights from Eli Lilly's Loxo
RE
02/12MARKET SNAPSHOT: Stocks Close At 2019 High On Tentative Deal To Avert Governm..
DJ
02/11Regeneron, Sanofi to Offer Praluent at Reduced U.S. List Price
DJ
02/11Sanofi and Regeneron cut list price of cholesterol drug by 60 percent
RE
02/06Eli Lilly Cuts Earnings Forecast on Pending Loxo Acquisition
DJ
More sector news : Biotechnology & Medical Research - NEC
Chart OSE IMMUNOTHERAPEUTICS
Duration : Period :
OSE Immunotherapeutics Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OSE IMMUNOTHERAPEUTICS
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 8,85 €
Spread / Average Target 115%
EPS Revisions
Managers
NameTitle
Alexis Peyroles Chief Executive Officer & Director
Dominique Costantini Chairman
Bernard Vanhove COO, Director-Research & Development
Anne-Laure Autret-Cornet Chief Financial Officer
Frédérique Corallo Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
OSE IMMUNOTHERAPEUTICS21.18%69
IQVIA HOLDINGS INC11.13%28 377
CELLTRION, INC.--.--%23 803
LONZA GROUP14.80%21 653
INCYTE CORPORATION31.18%17 908
SEATTLE GENETICS, INC.17.42%11 477